Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.

Autor: Delimpasi S; Department of Hematology and Bone Marrow Transplantation Unit, General Hospital Evangelismos, Athens, Greece., Dimopoulos MA; Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Straub J; Department of Internal Medicine - Hematology, University Hospital, Prague, Czech Republic., Symeonidis A; Department of Hematology, University General Hospital of Patras, Patras, Greece., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Hájek R; Department of Haematooncology, University Hospital Ostrava and Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Touzeau C; University Hospital Hôtel Dieu, Nantes, France., Bhanderi VK; Florida Cancer Specialists, Tallahassee Cancer Center, Tallahassee, Florida, USA., Berdeja JG; Sarah Cannon Research Institute, Nashville, Tennessee, USA., Pavlíček P; Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic., Matous JV; Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, Colorado, USA., Robak PJ; Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland., Suryanarayan K; Clinical Research, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Miller A; Statistics, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Villarreal M; Oncology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Cherepanov D; Global Evidence and Outcomes (GEO), Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Srimani JK; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Yao H; Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Labotka R; Oncology Clinical Research, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Orlowski RZ; Departments of Lymphoma/Myeloma and Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Sep; Vol. 99 (9), pp. 1746-1756. Date of Electronic Publication: 2024 Jun 10.